Please read the following Terms and Conditions before using the American Regent, Inc., (American Regent) Web site. By accessing and using the site, you acknowledge that you have read, understood, and agree to comply with these Terms and Conditions.

Amendment of Terms
American Regent may amend these Terms and Conditions at any time. Your continued use of this Web site is conditioned on the Terms and Conditions stated at the time of your use. You should visit this page prior to using this Web site to determine the current Terms and Conditions to which you are bound.

Content Disclaimer
The information on this Web site applies only to the products discussed herein as approved in the United States of America.

The information provided on this Web site is not intended to substitute for the advice of a physician or other health care provider. You should not use the information provided on this Web site to diagnose or treat any medical condition or to make any other decision. Read and follow all instructions provided with products or as directed by your health care provider.

The information found on this Web site is up-to-date only through its date of last revision, and may become out of date over time. American Regent accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information provided on this Web site.

Limitation of Warranties
The information provided on this Web site is provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT, to the extent allowed by applicable law.

Use Restriction
American Regent gives you permission to electronically copy and print in hard copy portions of the Web site for your personal, noncommercial use only. However, American Regent retains the copyright on all text, content, and graphics found on this Web site. This means that any other use, including, but not limited to, modification, distribution, or republication without American Regent's prior written permission is strictly prohibited. Nothing herein shall be considered to confer or grant any license or right under any copyright of American Regent, Inc.

Corporate Identification and Trademarks
The marks on the Web site are trademarks of American Regent, Inc., except for VENOFER® and DEXFERRUM®, which are registered trademarks of VIFOR (International) Inc., St. Gallen, Switzerland, used with permission under license ("the Licensed Marks"). You may not use, copy, reproduce, republish, upload, post, transmit, distribute, or modify these marks in any way without American Regent's prior written permission. The use of American Regent's trademarks, including the Licensed Marks, on any other Web site is prohibited.

Links
American Regent prohibits the use of American Regent's trademarks, including the Licensed Marks, as a "link" on or to any other Web site unless American Regent has approved the link in advance.

Nonconfidentiality
Any information supplied by a visitor to this Web site shall be deemed as nonconfidential. American Regent shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. American Regent shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including, but not limited to, developing, manufacturing, and marketing products incorporating such information.
American Regent. Enriching the lives of anemia patients. ™

IMPORTANT SAFETY INFORMATION: Venofer® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to Venofer® or any of its inactive components, and in patients with anemia not caused by iron deficiency. Serious hypersensitivity reactions have been reported in patients receiving Venofer®. In clinical studies, several patients experienced hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. The post-marketing spontaneous reporting system includes reports of patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with Venofer® administration.

Hypotension has been reported frequently in non-dialysis dependent-CKD patients receiving IV iron. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

In a multi-dose efficacy study in non-dialysis dependent-CKD patients (N=91), the most frequent adverse events (≥5%) whether or not related to Venofer® administration, were taste disturbance (7.7%), peripheral edema (7.7%), diarrhea (5.5%), constipation (5.5%), nausea (5.5%), dizziness (5.5%), and hypertension (5.5%). In an additional study of Venofer® with varying erythropoietin doses in 96 treated NDD-CKD patients, adverse events, whether or not related to Venofer® reported by ≥5% of Venofer® exposed patients are as follows: diarrhea (16.5%), edema (16.5%), nausea (13.2%), vomiting (12.1%), arthralgia (7.7%), back pain (7.7%), headache (7.7%), hypertension (7.7%), taste disturbance (7.7%), dizziness (6.6%), extremity pain (5.5%), and injection site burning (5.5%).

In multi-dose efficacy studies in HDD-CKD patients (N=231), the most frequent adverse events (> 5%) whether or not related to Venofer® administration, were hypotension (39.4%), muscle cramps (29.4%), nausea (14.7%), headache (12.6%), graft complications (9.5%), vomiting (9.1%), dizziness (6.5%) hypertension (6.5%), chest pain (6.1%), and diarrhea (5.2%). In post-marketing safety studies in HDD-CKD patients (N=1051), the most frequent adverse events reported (>1%), whether or not related to Venofer® administration, were congestive heart failure, sepsis, and taste disturbance. In the study of PDD-CKD patients (N=75), the most frequent adverse events, whether or not related to Venofer®, reported by ≥5% of these patients were diarrhea (8.0%), peritoneal infection (8.0%) vomiting (8.0%), hypertension (8.0%), pharyngitis (6.7%), peripheral edema (5.3%), and nausea (5.3%).


Please see Full Prescribing Information.